Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  sirolimus
Find trials that include:  Any drugs shown
Results 1-25 of 34 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Donor Peripheral Blood Stem Cell transplantation Followed by Lenalidomide and Sirolimus in Treating Patients With High-Risk Multiple Myeloma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 70
Trial IDs: IUCRO-0307, NCI-2011-00266, 1012-24, 1105005328, NCT01303965
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC1125, NCI-2012-00518, 11-001987, NCT01737502
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8027, NCI-2013-01614, NCT01938573
A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SARC023, NCI-2014-02429, NCT02008877
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, 00-C-0000, 150067, NCT02356159
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy using Sirolimus in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Pentostatin and Cyclophosphamide Followed by Donor Stem Cell Transplant and Donor Lymphocyte Infusions in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 08-C-0088, NCI-2009-00299, CDR0000648215, NCT00641485, 8242, NCT00923845
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Fludarabine Phosphate, Melphalan, and Total-Body Irradiation before Donor Double Umbilical Cord Blood Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 11-085, NCI-2012-00147, NCT01408563
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Donor Stem Cell Transplant in Treating Patients with GATA2 Mutations
Phase: Phase II
Type: Treatment
Age: 6 to 70
Trial IDs: 13-C-0132, NCI-2013-01561, 130132, P131226, NCT01861106
Sirolimus and Azacitidine in Treating Patients with High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That Is Relapsed or Refractory or Not Eligible for Intensive Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12D.587, NCI-2013-01004, 2012-50, NCT01869114
Clofarabine and Melphalan before Donor Stem Cell Transplant in Treating Patients with Myelodysplasia or Acute Leukemia in Remission
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 13130, NCI-2013-01193, 107819, NCT01885689
Bortezomib in Preventing Graft-Versus-Host Disease After Reduced-Intensity Donor Stem Cell Transplant in Patients With Hematologic Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 12-404, NCI-2013-00623, NCT01754389
Reduced Intensity Conditioning and Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Disease and Hemoglobinopathies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 70
Trial IDs: 121477, NCI-2013-00984, VICC BMT 12108, NCT01850108
In Vivo Treg Expansion and Graft-versus-Host Disease Prophylaxis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 18 and over
Trial IDs: MCC # 17578, NCI-2014-00755, NCT01927120
Nonmyeloablative Donor Stem Cell Transplant in Treating Patients with Congenital Anemias including Sickle Cell Disease and Thalassemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 55
Trial IDs: 012013-015, NCI-2014-02134, NCT02038478
Sirolimus, Everolimus, or Temsirolimus and Vorinostat in Treating Patients with Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2009-0729, NCI-2011-00562, NCT01087554
Donor Stem Cell Transplant in Treating Patients with DOCK8 Deficiency
Phase: Phase I
Type: Treatment
Age: 8 to 40
Trial IDs: 10-C-0174, NCI-2013-01462, 100174, P10665, NCT01176006
Sirolimus or Vorinostat in Combination with Hydroxychloroquine in Treating Patients with Advanced or Metastatic Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0588, NCI-2011-00303, NCT01266057
Sirolimus and Vismodegib in Treatment of Patients with Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MC1111, NCI-2011-03809, NCT01537107
Start Over